Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?

Nature Clinical Practice Urology volume 4, pages 304–305 (2007)Cite this article

boxed-textColombel M et al. (2006) The effect of ofloxacin on Bacillus Calmette–Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176: 935–939

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bohle A et al. (1996) The quality of life during intravesical bacillus Calmette–Guerin therapy. J Urol 155: 1221–1226

    Article  CAS  Google Scholar 

  2. Smith JA Jr et al. (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162: 1697–1701

    Article  Google Scholar 

  3. van der Meijden AP et al. (2001) Intravesical instillation of epirubicin, bacillus Calmette–Guerin and bacillus Calmette–Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166: 476–481

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. Department of Urology, University of Iowa, 200 Hawkins Dr, 3 RCP, Iowa City, IA 52242-1089, USA michael-odonnell@uiowa.edu

Authors and Affiliations

  1. M O'Donnell is Professor of Urology and Director of Urologic Oncology at the University of Iowa in Iowa City, IA, USA.,

    Michael O'Donnell

Authors
  1. Michael O'Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Donnell, M. Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?. Nat Rev Urol 4, 304–305 (2007). https://doi.org/10.1038/ncpuro0781

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0781

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing